Skip to main content
. 2017 Jan 13;8(8):13805–13817. doi: 10.18632/oncotarget.14638

Figure 2.

Figure 2

The final performance of the recurrence prediction model including all stage I and II samples is shown in (A) and (B). The performances with separated stage I and II samples are shown in (C) and (D). Patients in stages I and II had similar long-term DFS rates.